Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Bioorg Med Chem Lett ; 18(16): 4581-3, 2008 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-18657970

RESUMEN

A series of 10-hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones was synthesized and tested for their inhibition of HIV-1 replication in cell culture. Structure-activity studies indicated that high antiviral potency against wild-type virus as well as viruses containing integrase mutations that confer resistance to three different structural classes of integrase inhibitors could be achieved by incorporation of small aliphatic groups at certain positions on the core template. An optimal compound from this study, 16, inhibits integrase strand-transfer activity with an IC(50) value of 10 nM, inhibits HIV-1 replication in cell culture with an IC(95) value of 35 nM in the presence of 50% normal human serum, and displays modest pharmacokinetic properties in rats (i.v. t(1/2)=5.3 h, F=17%).


Asunto(s)
Química Farmacéutica/métodos , Integrasa de VIH/síntesis química , Integrasa de VIH/farmacología , Integrasas/genética , Mutación , Administración Oral , Animales , Antivirales/farmacología , Disponibilidad Biológica , Diseño de Fármacos , Humanos , Concentración 50 Inhibidora , Modelos Químicos , Ratas , Relación Estructura-Actividad , Replicación Viral
2.
Bioorg Med Chem ; 14(20): 6900-16, 2006 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-16870455

RESUMEN

Previous reports from our laboratories described potent tripeptide thrombin inhibitors which incorporate heterocycle-substituted chlorophenyl groups in the P1 position. Using these as lead compounds for further optimization, we identified sites of metabolism and designed analogs with 4-fluoroproline in P2 and cyclopropane-containing side chains in P3 as an approach to reducing metabolism and improving their oral pharmacokinetic performance. The large (300-fold) difference in potency between analogs containing (4R)- and (4S)-4-fluoroproline was rationalized by analyzing inhibitor-enzyme interactions in crystal structures of related compounds and by molecular modeling which indicated that the more potent (4R)-4-fluoroproline isomer stabilizes a proline ring conformation that is preferred for binding to the enzyme. An optimal compound from this work, 41, exhibits high potency in a coagulation assay in human plasma (2xAPTT=190 nM), excellent selectivity versus the digestive enzyme trypsin (K(i)=3300 nM), and excellent oral bioavailability in dogs with moderate clearance (F=100%, CL=12 mL/min/kg).


Asunto(s)
Inhibidores Enzimáticos/farmacología , Prolina/análogos & derivados , Trombina/antagonistas & inhibidores , Sitios de Unión , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Humanos , Técnicas In Vitro , Modelos Moleculares , Conformación Molecular , Prolina/química , Conformación Proteica , Estructura Terciaria de Proteína , Estereoisomerismo , Relación Estructura-Actividad , Trombina/metabolismo , Tripsina/efectos de los fármacos , Tripsina/metabolismo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda